A B S T R A C T
Hypertension is the number one cardiovascular (CV) risk factor, and its treatment represents one of the most important interventions in patients at high risk for CV events. Patients with chronic kidney disease (CKD) are at high CV risk, yet as a group they have been excluded from most major blood pressure (BP)-lowering trials examining CV and mortality end points. The paucity of randomized clinical trial evidence for BP lowering in CKD patients is compounded by the fact that the association between BP levels and clinical outcomes in patients with CKD suggests the presence of a J-curve, which makes extrapolations from general population studies especially difficult. The recent completion of the Systolic Blood Pressure Intervention Trial (SPRINT), which enrolled a large number of patients with mild to moderate CKD, has raised hope for much-needed clarity about the ideal systolic BP target in this patient population. This review discusses the epidemiology of hypertension in CKD and the pathophysiologic underpinnings of the distinct associations between BP levels and clinical outcomes in patients with CKD, and it examines the applicability of the SPRINT results to the general CKD population.
Keywords: blood pressure, cardiovascular, chronic kidney disease, CKD, hypertension, mortality
I N T R O D U C T I O N
Hypertension remains the number one risk of cardiovascular (CV) disease and mortality in the general population [1] [2] [3] , and lowering elevated blood pressure (BP) has been advocated as an effective means to prevent adverse CV events [4] . Given the apparently linear association of BP levels with higher morbidity and mortality in the general population, stricter BP control has been promoted for populations are considered to be at increased risk for CV events, such as patients with diabetes mellitus (DM) and chronic kidney disease (CKD) [4, 5] . However, such recommendations were based on extrapolations and not on results obtained from randomized controlled trials (RCTs) in these patient populations [5] . Contradicting arguments in favor of stricter BP control in CKD are observations that the association of systolic BP (SBP) and diastolic BP (DBP) levels with mortality in patients with advanced CKD and end-stage renal disease (ESRD) is qualitatively different, i.e. these populations experience a reverse J-shaped or even an inverse association between BP levels and clinical outcomes [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . Reasons for such seemingly paradoxical associations include pathologically altered autoregulatory mechanisms in patients with advanced vascular disease states, potentially excessive lowering of DBP when attempting to treat elevated SBP in patients with isolated systolic hypertension [16, 17] or competing risks from causes of death unrelated to hypertension in populations with high comorbidity burden or advanced age. Short of definitive RCTs, the debate about the ideal target BP in CKD seemed to be at an impasse such that the (strictly RCT-guided) 2014 EvidenceBased Guideline for the Management of High Blood Pressure in Adults: Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) recommendations advocating less stringent BP treatment targets in some patient populations [18] were met with dissent even from within the JNC 8 committee [19] .
Upon this background, the Systolic Blood Pressure Intervention Trial (SPRINT) was the first major BP-lowering RCT aimed at improving mortality and CV events that was designed to enroll patients with CKD, and as such, it offered hope to clarify whether or not stricter BP targets could be beneficial in this population. SPRINT showed a clear and robust benefit linked to strict BP control [20] , to the extent that the trial was terminated early by its data safety monitoring board. Notwithstanding the impressive benefits of strict BP control in SPRINT, enthusiasm about its results has been muted in the nephrology community, mainly due to concerns about the practical applicability of its findings. This review will examine the background upon which hypertension therapy in CKD is considered unique and will also discuss still existing concerns and open questions about ideal BP targets in this population in the wake of SPRINT.
There are indications from population-based studies that the nature of BP in patients with CKD is different: compared with patients with no CKD, their SBP is similar, their DBP is lower, their pulse pressure is higher and they receive antihypertensive therapy much more often [16] . Besides a general concern about vascular pathophysiology underlying such differences (vide infra), much of the controversy about the role of BP in patients with kidney disease stems from studies that indicated an inverse association between BP and adverse outcomes in dialysis patients, in whom often the highest BP levels were associated with the best outcomes [7] [8] [9] [10] [11] [12] . Studies in small, single-center cohorts of patients with nondialysis-dependent CKD also indicated similarly paradoxical associations [13, 15] . In a secondary analysis of the Irbesartan Diabetic Nephropathy Trial, a lower achieved BP was associated with higher mortality and CV risk, except for strokes [14] . More recently, in a large national cohort of 651 749 US veterans with prevalent CKD [mean estimated glomerular filtration rate (eGFR) 50 6 14 mL/min/1.73 m 2 ] both SBP and DBP displayed U-shaped associations with allcause mortality, with the lowest mortality experienced by patients with BPs of 130-160/70-90 mmHg [6] . This study also examined associations between granular categories of combined SBP/DBP pairs and found that DBP levels below 70 mmHg were associated with higher mortality independent of SBP levels, unless the latter were elevated to very high levels (>180 mmHg).
The reverse J-shaped phenomenon for BP has been observed in other populations besides those with CKD and ESRD [21] [22] [23] [24] , the obvious caveat in all cases being that causality cannot be inferred from observational studies, and the low BP levels seen in patients with the highest mortality may be a result of comorbid conditions such as advanced congestive heart failure (CHF) which could thus confound the association of low BP with mortality. One way that observational studies could overcome such unmeasured confounding is by modeling retrospectively the process of a clinical trial. In the case of hypertension therapy, this would consist of identifying patients with uncontrolled hypertension (based on BP levels and/or use of antihypertensive therapy) and then of the subsequent detection of lower BP in the face of enhanced antihypertensive therapy. In such a modeling study performed in a large cohort of US veterans with nondialysis-dependent CKD, patients who developed an SBP <120 mmHg experienced higher all-cause mortality compared with those whose BP decreased to 120-140 mmHg [25] . This study suggested that therapeutically lowering SBP to <120 mmHg may be deleterious, although its observational nature still mandates caution when interpreting its results.
One characteristic of CKD populations is that they tend to be much older compared with the general population. Age being a major defining factor in vascular pathophysiology, it is often believed that older patients may need special considerations when defining hypertension treatment targets [18] . Furthermore, older individuals experience much higher mortality rates compared with younger ones, and these deaths may or may not be related to mechanisms linked to high BP (such as CV events). Indeed, causes of death such as malignancies or infections could be disproportionately higher among older adults, and hence the effects of BP levels (and consequently hypertension therapy) on mortality may be different in them. Two recent studies examining the association of BP with mortality in patients with CKD found that overall the association was U-shaped, and while high SBP was associated with higher mortality in all age groups, this association was less accentuated in older individuals, especially those >80 years old [26, 27] . In a cohort of 339 887 patients with incident CKD, the hazard ratios associated with SBP 170 mmHg (versus the referent 130-139 mmHg) in patients <50, [26] , indicating progressively weaker associations between elevated SBP and all-cause mortality in older individuals. Furthermore, the SBP range associated with the lowest mortality rate among the oldest age group in this study was 120-160 mmHg, which was wider than what was seen in younger individuals (120-140 mmHg) [26] .
As indicated above, the type and the number of clinical events seen in a given population may have a profound effect on the role BP has in such patients, and ultimately the effect of BPlowering therapies on outcomes in these patients. In groups where vascular pathology plays a more accentuated role in clinical outcomes, high BP is expected to have a stronger role in defining outcomes and hypertension therapy a more robust effect on preventing them. The above-mentioned study of 339 887 patients with incident CKD examined associations between BP levels and incident coronary heart disease (CHD), ischemic stroke and ESRD [26] . Higher SBP was associated with linearly higher risk of these outcomes, in stark contrast to the U-shaped associations seen with all-cause mortality in the same study. The associations were present in all age groups, albeit they were weaker in patients of more advanced age. With various outcomes competing, the relative importance of BP (and antihypertensive therapy) in any given population will be determined by the relative frequency of events directly impacted by BP versus those unaffected by it. Figure 1 illustrates crude event rates for all-cause mortality, incident CHD, stroke and ESRD in various age groups among the above cohort of 339 887 incident CKD patients [26] . With all four event types shown on an identical scale, it is obvious that in younger patients the frequency of ii220 C.P. Kovesdy
all-cause mortality and the various vascular events are comparable with each other. This is in stark contrast with their relative frequencies among older individuals, among whom deaths outnumbered vascular events by a wide margin, underscoring the importance of causes of deaths when examining the effects of BP lowering in older patient groups.
P A T H O P H Y S I O L O G I C C O N S I D E R A T I O N S O F B L O O D P R E S S U R E I N C K D
Various hypotheses have been put forth to reconcile the reverse J-shaped phenomenon in the association of BP with outcomes in CKD patients. The BP levels characteristically seen in patients with CKD (i.e. low DBP and high pulse pressure) may be signaling increased vascular stiffness and/or a high burden of comorbidities such as CHF or frailty [28] , which could result in the phenomenon of reverse causation in observational studies. On the other hand, low BP could also cause direct harm by compromising the blood supply of various organs; such an effect may be especially important in the case of low DBP compromising coronary perfusion in patients with preexisting coronary artery disease. Supporting this hypothesis are observations that there is a decreased tolerance of lower (and higher) BPs in certain patient populations; this is typically the result of pathologic changes in vascular structure (such as arteriolar endothelial dysfunction, hyaline arteriosclerosis and myointimal hyperplasia [29] [30] [31] [32] ), which lead to compromised vascular autoregulation and thus a limited ability to adapt to fluctuations in BP levels [33] . These phenomena are observed predominantly in elderly patients, and in individuals with certain comorbidities such as CKD, chronic hypertension or atherosclerosis [34] , which may explain the reverse J-shaped phenomenon observed in the studies detailed above.
E F F E C T S O F B P L O W E R I N G I N T H E C K D S U B G R O U P O F S P R I N T
The overarching aim of SPRINT was to test a strict versus a conventional SBP treatment target (defined as <120 versus <140 mmHg) toward lowering mortality and CV end points among patients at high CV risk [20] . The CKD subgroup of SPRINT consisted of 2646 patients (28% of the total SPRINT population) with an eGFR of 20-<60 mL/min.1.73 m 2 and proteinuria <1 g/day; diabetics and those with a diagnosis of a primary glomerulonephritis were excluded. Overall, SPRINT showed an overwhelmingly positive effect of strict SBP lowering in the overall study population, with an 25% relative risk reduction for the primary composite end point compared with the conventional SBP-lowering strategy, and significant reductions in multiple secondary end points including all-cause mortality [20] . In patients with preexisting CKD, strict SBP lowering resulted in an 18% reduction in the primary composite end point compared with the conventional SBP target [hazard ratio 0.82 (95% CI 0.63-1.07)]. While this reduction in risk was not statistically significant, a test for interaction was nonsignificant (P ¼ 0.36), suggesting that the difference may have been due to sample size and not to fundamentally different effects of SBP lowering in the CKD subgroup. Furthermore, reduction in allcause mortality was identical in patients with and without CKD and statistically significant in both groups [hazard ratio in the CKD subgroup 0.73 (95% CI 0.53-1.00)]. There was no difference in renal outcomes in SPRINT: patients with preexisting CKD treated to the two different SBP targets experienced identical incidences of a composite renal outcome and of individual events of a 50% decline in eGFR, dialysis start, kidney transplantation and incident albuminuria. The total number of renal events was very small, with only 29 total composite renal outcomes. Other notable renal-related findings from SPRINT FIGURE 1: Event rates (95% CIs) for all-cause mortality, incident coronary heart disease, incident ischemic stroke and end-stage renal disease associated with various SBP levels in individuals of various age among a cohort of 339 887 patients with incident CKD. Event rates are expressed as event/1000 patient-years. (Based on reanalyzed data from Kovesdy et al. [26] .) H y p e r t e n s i o n t r e a t m e n t i n C K D a f t e r S P R I N T ii221
included a higher incidence of acute kidney injury and higher incidences of hyponatremia and hypokalemia in the strict SBPlowering arm [20] . Further details about CKD-specific aspects of SPRINT are awaited from pending publications.
I S S P R I N T G E N E R A L I Z A B L E T O A L L P A T I E N T S W I T H C K D ?
SPRINT had extremely good internal validity, and hence its results convincingly prove the benefits of lowering SBP to <120 mmHg in patients who are similar to those included in the trial. However, there remain questions about how to apply the results from SPRINT to the wider CKD patient population (Table 1) .
Case mix and causes of death
A crucial question for all clinical trials (including those with excellent internal validity) is their external validity, i.e. whether or not the results of the tested intervention can be applied to a wider patient population [36] . The SPRINT enrolled patients at high CV risk, but the exclusion of diabetic patients or of those with high-grade proteinuria render the SPRINT cohort different in some key characteristics compared with the wider CKD population, especially in light of a lack of benefit seen in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial from strict SBP control in diabetic patients [37] . Importantly, the mortality rate experienced by SPRINT participants was substantially lower compared with what is seen in the CKD population (Table 1) , suggesting important (albeit ill-defined) differences that are probably a result of selection bias (sicker patients are typically excluded from or are not prone to participating in clinical trials). Another important aspect of how a certain group's mortality is affected by BP-lowering therapy is the cause of their deaths (vide supra). Thirty-five percent of the deaths recorded in SPRINT were attributed to CV causes (102 deaths, versus 192 deaths attributed to non-CV causes), and a benefit of strict SBP lowering was only seen for deaths attributable to CV causes (37 deaths in the strict SBP-lowering arm versus 65 deaths in the conventional SBP-lowering arm) as opposed to deaths not attributed to CV causes (90 versus 102 deaths in the strict and conventional SBP-lowering arms, respectively). Causes of death may be substantially different in the general CKD population. In a recent analysis of a large Korean cohort of 367 932 patients, age-standardized CV deaths comprised 19.6% of all deaths in those with an eGFR <45 mL/ min/1.73 m 2 , while cancer-related and non-CV/noncancerrelated deaths made up 30.9 and 49.5% of all deaths, respectively [38] .
BP measurement
The SPRINT tested a 'strict' versus a 'conventional' SBP target and achieved mean SBP levels of 121 versus 136 mmHg after 1 year [20] . It is debatable whether these levels can be translated to levels obtained in clinical practice (and by the same token to levels examined in observational studies using clinical data). The BP measurement method used in SPRINT was one where the examiner left the room and an automated device measured the patients' BP after several minutes. It has been estimated that using this method can result in measured BP levels that are 5-20 mmHg lower compared with methods typically applied in clinical practice [35] . It is therefore possible that the SBP achieved in the 'strict' control arm of SPRINT could correspond to SBP levels of 120-140 mmHg in routine clinical practice, which have in fact been associated with the lowest mortality rates in large observational studies of CKD populations [6, 25, 26] .
Considering the totality of evidence, it is the author's opinion that an SBP target of <120 mmHg should not be applied to all patients with CKD, and even in patients whose clinical characteristics are very similar to the SPRINT participants, such strict targets should only be applied with recognition of the effects of the applied BP measurement method and of individual tolerance of therapy.
C O N C L U S I O N S
Hypertension is undoubtedly the most important CV risk factor, and one that is common and imminently treatable. This makes ongoing efforts to find the ideal treatment target in all hypertensive patients extremely important. The SPRINT represents a major step forward in our understanding of how to treat hypertension in patients with CKD. Due to differences in key clinical and outcome characteristics compared with the wider CKD population, extrapolation of the SPRINT findings to all patients with CKD is not possible. Furthermore, due to the method used to record BP in SPRINT participants, it is possible that SPRINT in fact corroborates, rather than refutes, results from other trials such as ACCORD [37] and from large observational studies in CKD patients [6, 25, 26] . Pending further clarification, it seems prudent to continue to adhere to existing clinical guidelines for BP therapy in CKD and to consider individual patient characteristics when devising treatment interventions for hypertension in this patient population.
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